CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

Last updated: November 8, 2019
Sponsor: iCell Gene Therapeutics
Overall Status: Active - Recruiting

Phase

1

Condition

Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Treatment

N/A

Clinical Study ID

NCT04156243
ICG134-001
  • All Genders

Study Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Diagnosis based on the World Health Organization (WHO) 2008

  2. Patients have exhausted standard therapeutic options

  3. Systematic usage of immunosuppressive drug or corticosteroid must have been stoppedfor more than 4 weeks

  4. Female must be not pregnant during the study

Exclusion

Exclusion Criteria:

  1. Prior solid organ transplantation

  2. Potentially curative therapy including chemotherapy or hematopoietic cell transplant

  3. Prior treatment with BCMAxCD3 or CS1xCD3 bispecific agents

Study Design

Total Participants: 20
Study Start date:
February 01, 2018
Estimated Completion Date:
February 28, 2020

Study Description

CD19 CARvac is a chimeric antigen receptor immunotherapy treatment designed to treat

Connect with a study center

  • The General Hospital of Western Theater Command

    Chengdu,
    China

    Active - Recruiting

  • Peking University Shenzhen Hospital

    Shenzhen,
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.